What Sirona Biochem does

Sirona Biochem Corp. is a Vancouver-based, publicly traded (CVE:SBM) biotechnology company founded in 2006 that develops and licenses proprietary compounds to global customers in the cosmetic ingredients and pharmaceutical drug discovery sectors. Its product surface is concentrated in dermatological and anti-aging applications, including skin depigmenting and anti-aging agents, anchored by a proprietary chemistry platform whose core IP traces to the 2011 acquisition of TFChem. The company is led by founder, Chairman and CEO Howard J. Verrico, with Christopher Hopton as CFO, Géraldine Deliencourt-Godefroy as CSO, and Michelle Seltenrich as VP of Operations, supported by a small team of 11-50 employees.

The business model is asset-light and contract-based: Sirona generates revenue by licensing its proprietary compounds to global cosmetic, skincare, and pharmaceutical companies for use in their product formulations and drug discovery pipelines. Pricing and contract economics are not publicly disclosed, and no named licensees are available in the source data. The customer base spans two use-case segments — a primary cosmetic ingredients segment serving companies seeking differentiated anti-aging and skincare actives, and a secondary pharmaceutical/drug discovery segment — with a horizontal segmentation approach. In April 2025 the company added a strategic layer through Promura GmbH, which invested CAD $3 million via convertible debentures and co-formed Sirona Laboratories, a jointly controlled joint venture in Luxembourg, with Promura signaling up to CAD $12 million of follow-on capital contingent on due diligence to advance dermatological and cosmetic innovation. Subsequent capital activity in 2026 has shifted to debt, including CAD $1 million loan and promissory note arrangements with 0906462 B.C. Ltd., consistent with working-capital bridging while larger strategic capital remains contingent.

Name

Sirona Biochem

Legal name

Sirona Biochem Corp.

Website

https://sironabiochem.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Sirona Biochem Corp. is a Vancouver-based public biotechnology company that develops and licenses proprietary compounds — primarily anti-aging and skin depigmenting actives — to global cosmetic ingredients and pharmaceutical drug discovery customers, anchored by the TFChem chemistry platform and a 2025 joint venture with Promura GmbH.

Ownership category

akta.pro rank

Product category

Biotechnology & Pharmaceutical Licensing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Cosmetic ingredient licensing
• Biotechnology compound development
• Anti-aging skincare compounds
• Dermatological drug discovery
• Proprietary biochemical compounds

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Compound Licensing: Sirona Biochem licenses its proprietary compounds to global companies in the cosmetic and pharmaceutical industries.

Core offering

Sirona Biochem develops proprietary biological and chemical compounds — including anti-aging agents, skin depigmenting agents, and diabetes therapeutics — and licenses them to global companies in the cosmetic and pharmaceutical industries. The company operates as a compound licensor rather than a finished-product manufacturer, monetizing its IP portfolio through royalty and licensing agreements. Its scientific foundation stems from the 2011 acquisition of TFChem, and its dermatological focus is being scaled via the 2025 Sirona Laboratories joint venture in Luxembourg.

Product overview

Sirona Biochem specializes in cosmetic ingredient development and drug discovery. The company licenses proprietary compounds to global companies. Through its joint venture Sirona Laboratories (formed with Promura GmbH in Luxembourg), the company focuses on dermatological and cosmetic innovation, particularly anti-aging products. However, no specific named products or detailed product information are available in the provided sources.

Differentiator

Problem solved

Functional benefit

Products and services

• Anti-aging cosmetic compounds
• Skin depigmenting agents
• Diabetes therapeutics

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Sol-Gel Technologies: Clinical-stage dermatology company developing topical branded and generic products. Comparable small-cap dermatology biotech with proprietary formulation/IP-led pipeline similar to Sirona's compound-licensing approach.
• Lexicon Pharmaceuticals: Clinical-stage biopharma developing treatments for diabetes and metabolic disease. Comparable small-cap biotech with similar licensing/partnership-driven commercial model in cardiometabolic indications.
• Revance Therapeutics: Specialty aesthetics/dermatology biotech focused on injectable and topical products. Highly comparable to Sirona's dermatology/anti-aging compound development and licensing-oriented commercialization model.
• Arcutis Biotherapeutics: Dermatology-focused biopharma developing novel topical therapies. Direct peer in the dermatology specialty pharmaceutical space with comparable size and licensing/partnering strategy.
• Evolus: Aesthetic medicine biotech commercializing injectable and topical products. Comparable small-cap aesthetics biotech with licensing-driven commercial model relevant to Sirona's anti-aging focus.
• Zealand Pharma: Small-cap clinical biotech developing peptide therapeutics for diabetes and metabolic diseases. Closely comparable to Sirona's diabetes therapeutic pipeline on both indication and company scale.

Broad incumbents

• Galderma: Global dermatology leader with broad prescription, aesthetic, and consumer skincare portfolio. Operates in the same dermatology/anti-aging space and is a likely licensing counterparty or competitor for Sirona's compounds.
• AbbVie (Allergan Aesthetics): Global pharmaceutical incumbent with a leading aesthetics franchise (Botox, CoolSculpting, SkinMedica). Operates broadly in the same dermatology/aesthetics space and is a potential partner or acquirer for Sirona's anti-aging assets.

Emerging players

• Lipidor AB: Swedish specialty pharma/cosmeceutical developer using proprietary lipid-based delivery technology. Small-cap peer with a similar licensing-oriented model in dermatology and skin care.
• Mibelle Group: Swiss developer of proprietary cosmetic and skincare active ingredients. Comparable to Sirona as a cosmeceutical ingredient developer with licensing relationships to global beauty brands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/SironaBiochem
• Facebookfacebook.com/110521942342739
• LinkedInlinkedin.com/company/sirona-biochem-corp.

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sirona Biochem